First Patient Dosed in G308 Paediatric Trial

Allergy Therapeutics PLC

27 November 2024

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics announces first patient treated in G308 Phase III trial to evaluate long-term efficacy and safety of Grass MATA MPL in paediatric patients

-       Industry first long-term subcutaneous allergen-specific immunotherapy trial in paediatric subjects with grass induced allergic rhinitis

27 November 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that the first subject has been treated in the Phase III G308 trial to evaluate the long-term efficacy and safety of Grass MATA MPL in paediatric subjects. 

Grass MATA MPL incorporates MicroCrystalline Tyrosine adsorbed allergoids and the adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only requires patients to receive six doses prior to the grass allergy season.

Treatment initiation in the G308 paediatric trial follows, as previously announced, the completion of the Group's pivotal Phase III G306 trial in adults and subsequent submission of Marketing Authorisation Application to the Paul Ehrlich Institut in Germany. Grass MATA MPL has demonstrated a highly statistically significant and clinically relevant reduction in the Combined Symptom & Medication Score compared to placebo over the peak pollen season in adults and the G308 trial is designed to evaluate long-term efficacy and safety in a paediatric population.

Manuel Llobet, CEO of Allergy Therapeutics, commented: "The start of the Phase III G308 trial investigating the efficacy and safety of our Grass MATA MPL in a paediatric population marks an exciting step in bringing this innovative treatment to further patients affected by grass allergies. Building on our successful adult trials, this study will help us understand how our short-course immunotherapy can benefit children affected by grass allergies, potentially transforming their treatment journey."

- ENDS -

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

[phone]

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

About Grass MATA MPL

Grass MATA MPL is being developed as a subcutaneous immunotherapy product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduces the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

 

END